--- schema_version: "secwatch.filing_event.v1" accession: "0001493152-23-029981" form_type: "8-K" ticker: "ASBP" cik: "0001847345" company_name: "Aspire Biopharma Holdings, Inc." filed_at: "2023-08-23T23:59:59+00:00" generated_at: "2026-06-11T04:59:11.577319+00:00" event_type: "other_material" sentiment: "neutral" materiality_score: 0.8 calibrated_materiality_score: 0.8 confidence: "high" source: SEC EDGAR --- # PowerUp Acquisition Corp. changes sponsor, board and officers; new CEO appointed ## Summary - New sponsor SRIRAMA Associates acquired 4,317,500 Class A shares and 6,834,333 warrants for $1 total. - All prior directors (Hack, Tretton, Blacklow, Uhrman, Campbell) and officers resigned. - Surendra Ajjarapu appointed CEO and Chairman; Howard Doss appointed CFO. - Trust account true-up payment of ~$0.02/share paid to redeeming shareholders on Aug 18, 2023. - New independent directors: Michael Peterson, Donald Fell, Mayur Doshi, Avinash Wadhwani. ## SEC filing metadata - accession: 0001493152-23-029981 - form_type: 8-K - ticker: ASBP - cik: 0001847345 - company_name: Aspire Biopharma Holdings, Inc. - filed_at: 2023-08-23T23:59:59+00:00 - event_type: other_material - sentiment: neutral - materiality_score: 0.8 - calibrated_materiality_score: 0.8 - confidence: high - sec_items: 1.01, 5.02, 8.01, 9.01 - EDGAR index: https://www.sec.gov/Archives/edgar/data/1847345/000149315223029981/0001493152-23-029981-index.htm - EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1847345/000149315223029981/form8-k.htm ## Machine-readable alternates - HTML: https://secwatch.observer/filing/0001493152-23-029981 - JSON: https://secwatch.observer/filing/0001493152-23-029981.json - Plain text: https://secwatch.observer/filing/0001493152-23-029981.txt ## Key facts - Executive change Kyle Campbell resigned as director at Aspire Biopharma Holdings, Inc.. - Action: resigned - Role: director source text: (i) Bruce Hack, Jack Tretton, Peter Blacklow, Julie Uhrman, and Kyle Campbell (the “Resigning Directors”) tendered their resignations as members of the board of directors of the Company (the “Board”) evidence_url: https://www.sec.gov/Archives/edgar/data/1847345/000149315223029981/0001493152-23-029981-index.htm - Executive change Michael L. Peterson was appointed as director at Aspire Biopharma Holdings, Inc.. - Action: appointed - Role: director source text: (iii) Surendra Ajjarapu, Michael L. Peterson, Donald G. Fell, Mayur Doshi, and Avinash Wadhwani were appointed as members of the Board (each, a “New Director”) evidence_url: https://www.sec.gov/Archives/edgar/data/1847345/000149315223029981/0001493152-23-029981-index.htm - Executive change Gabriel Schillinger resigned as other_named_officer at Aspire Biopharma Holdings, Inc.. - Action: resigned source text: (ii) Jack Tretton, Michael Olson, and Gabriel Schillinger resigned as officers of the Company evidence_url: https://www.sec.gov/Archives/edgar/data/1847345/000149315223029981/0001493152-23-029981-index.htm - Executive change Avinash Wadhwani was appointed as director at Aspire Biopharma Holdings, Inc.. - Action: appointed - Role: director source text: (iii) Surendra Ajjarapu, Michael L. Peterson, Donald G. Fell, Mayur Doshi, and Avinash Wadhwani were appointed as members of the Board (each, a “New Director”) evidence_url: https://www.sec.gov/Archives/edgar/data/1847345/000149315223029981/0001493152-23-029981-index.htm - Executive change Michael Olson resigned as other_named_officer at Aspire Biopharma Holdings, Inc.. - Action: resigned source text: (ii) Jack Tretton, Michael Olson, and Gabriel Schillinger resigned as officers of the Company evidence_url: https://www.sec.gov/Archives/edgar/data/1847345/000149315223029981/0001493152-23-029981-index.htm - Executive change Bruce Hack resigned as director at Aspire Biopharma Holdings, Inc.. - Action: resigned - Role: director source text: (i) Bruce Hack, Jack Tretton, Peter Blacklow, Julie Uhrman, and Kyle Campbell (the “Resigning Directors”) tendered their resignations as members of the board of directors of the Company (the “Board”) evidence_url: https://www.sec.gov/Archives/edgar/data/1847345/000149315223029981/0001493152-23-029981-index.htm - Executive change Jack Tretton resigned as director at Aspire Biopharma Holdings, Inc.. - Action: resigned - Role: director source text: (i) Bruce Hack, Jack Tretton, Peter Blacklow, Julie Uhrman, and Kyle Campbell (the “Resigning Directors”) tendered their resignations as members of the board of directors of the Company (the “Board”) evidence_url: https://www.sec.gov/Archives/edgar/data/1847345/000149315223029981/0001493152-23-029981-index.htm - Executive change Surendra Ajjarapu was appointed as director at Aspire Biopharma Holdings, Inc.. - Action: appointed - Role: director source text: (iii) Surendra Ajjarapu, Michael L. Peterson, Donald G. Fell, Mayur Doshi, and Avinash Wadhwani were appointed as members of the Board (each, a “New Director”) evidence_url: https://www.sec.gov/Archives/edgar/data/1847345/000149315223029981/0001493152-23-029981-index.htm - Executive change Jack Tretton resigned as other_named_officer at Aspire Biopharma Holdings, Inc.. - Action: resigned source text: (ii) Jack Tretton, Michael Olson, and Gabriel Schillinger resigned as officers of the Company evidence_url: https://www.sec.gov/Archives/edgar/data/1847345/000149315223029981/0001493152-23-029981-index.htm - Executive change Peter Blacklow resigned as director at Aspire Biopharma Holdings, Inc.. - Action: resigned - Role: director source text: (i) Bruce Hack, Jack Tretton, Peter Blacklow, Julie Uhrman, and Kyle Campbell (the “Resigning Directors”) tendered their resignations as members of the board of directors of the Company (the “Board”) evidence_url: https://www.sec.gov/Archives/edgar/data/1847345/000149315223029981/0001493152-23-029981-index.htm - Executive change Donald G. Fell was appointed as director at Aspire Biopharma Holdings, Inc.. - Action: appointed - Role: director source text: (iii) Surendra Ajjarapu, Michael L. Peterson, Donald G. Fell, Mayur Doshi, and Avinash Wadhwani were appointed as members of the Board (each, a “New Director”) evidence_url: https://www.sec.gov/Archives/edgar/data/1847345/000149315223029981/0001493152-23-029981-index.htm - Executive change Surendra Ajjarapu was appointed as Chairman of the Board at Aspire Biopharma Holdings, Inc.. - Action: appointed - Role: Chairman of the Board source text: (iv) Surendra Ajjarapu was appointed Chairman of the Board evidence_url: https://www.sec.gov/Archives/edgar/data/1847345/000149315223029981/0001493152-23-029981-index.htm - Executive change Howard Doss was appointed as Chief Financial Officer at Aspire Biopharma Holdings, Inc.. - Action: appointed - Role: Chief Financial Officer source text: (v) Surendra Ajjarapu and Howard Doss were appointed as the Company’s Chief Executive Officer and Chief Financial Officer, respectively (each, a “New Officer”). evidence_url: https://www.sec.gov/Archives/edgar/data/1847345/000149315223029981/0001493152-23-029981-index.htm - Executive change Mayur Doshi was appointed as director at Aspire Biopharma Holdings, Inc.. - Action: appointed - Role: director source text: (iii) Surendra Ajjarapu, Michael L. Peterson, Donald G. Fell, Mayur Doshi, and Avinash Wadhwani were appointed as members of the Board (each, a “New Director”) evidence_url: https://www.sec.gov/Archives/edgar/data/1847345/000149315223029981/0001493152-23-029981-index.htm - Executive change Julie Uhrman resigned as director at Aspire Biopharma Holdings, Inc.. - Action: resigned - Role: director source text: (i) Bruce Hack, Jack Tretton, Peter Blacklow, Julie Uhrman, and Kyle Campbell (the “Resigning Directors”) tendered their resignations as members of the board of directors of the Company (the “Board”) evidence_url: https://www.sec.gov/Archives/edgar/data/1847345/000149315223029981/0001493152-23-029981-index.htm - Executive change Surendra Ajjarapu was appointed as Chief Executive Officer at Aspire Biopharma Holdings, Inc.. - Action: appointed - Role: Chief Executive Officer source text: (v) Surendra Ajjarapu and Howard Doss were appointed as the Company’s Chief Executive Officer and Chief Financial Officer, respectively (each, a “New Officer”). evidence_url: https://www.sec.gov/Archives/edgar/data/1847345/000149315223029981/0001493152-23-029981-index.htm - Material Agreements Aspire Biopharma Holdings, Inc. entered into Purchase Agreement with PowerUp Sponsor LLC, SRIRAMA Associates, LLC valued at aggregate purchase price of $1.00 for 4,317,500 Class A ordinary shares and 6,834,333 private placem (effective 2023-08-18). - Action: entry - Agreement: equity purchase - Counterparty: PowerUp Sponsor LLC, SRIRAMA Associates, LLC - Value: aggregate purchase price of $1.00 for 4,317,500 Class A ordinary shares and 6,834,333 private placem - Effective: 2023-08-18 source text: on July 14, 2023, PowerUp Acquisition Corp., a Cayman Islands exempted company (the “Company”), entered into a purchase agreement (the “Purchase Agreement”) with PowerUp Sponsor LLC, a Delaware limited liability company (the “Original Sponsor”) and SRIRAMA Associates, LLC, a Delaware limited liability company (the “New Sponsor”), pursuant to which the New Sponsor agreed to purchase from the Original Sponsor 4,317,500 Class A ordinary shares, of the Company and 6,834,333 private placement warrants, each exercisable for one Class A Ordinary Share for an aggregate purchase price of $1.00 evidence_url: https://www.sec.gov/Archives/edgar/data/1847345/000149315223029981/0001493152-23-029981-index.htm This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.